Performance study - application/notification form under *In Vitro* Diagnostic Medical Devices Regulation (IVDR)

Application/notification form version

Section 1: Performance study identification			
1.1 Sponsor	<u>identification</u>		
Name:			
Address	Street name:	Street number:	
	Postal code:	City:	
	Country:		
	Country.		
Telephone ni	umber:		
Email:			
	Contact person of the sponsor		
First name:			
Last name:			
Last name.			
Telephone nu	umber:		
Email:			
-			
	Change de logal rouves ontative identification		
Do you have	<u>Sponsor's legal representative identification</u> a legal representative?		
Do you nave	a iegai representative:		
Yes	No		
If yes, comple	ete the information related to the legal representative (section 1.2)	

1.2 Legal representative identification				
Organisatio	n name:			
Address	Street name:	Street number:		
	Postal code:	City:		
	Country:			
Telephone r	number:			
Email:				
	Contact person of the legal re	presentative		
First name:				
Last name:				
Telephone number:				
Email:				
	Contact person for the perfor	mance study		
Same as contact person of sponsor				
Sam	e as contact person of legal repre	sentative		
Othe	er			
If you selected other, please fill in the section below related to the other contact person for this performance study.				

Other contact person for the performance study First name: Last name: Address Street name: Street number: Postal code: City: Country: Telephone number: Email: 1.3 Performance study type Select the appropriate regulatory pathway for the application: Performance study application (IVDR Art. 58 (1&2)) PMPF study notification (IVDR Art. 70(1)) Performance study notification involving companion diagnostics using left-over samples only. (IVDR Art. 58(2)) 1.4 Submission type First submission in the EEA, if available, provide the performance study ID (PS-ID) First submission at the national level (performance study has been already submitted in EEA). In this case, please provide the CIV-ID Resubmission. Please provide the CIV-ID

1.5 Participating countries within the EU/EEA/UK (Northern Ireland), Turkiye and Switzerland
Select the participating countries for the performance study
1.6 Participating countries outside EU/EEA/UK (Northern Ireland), Turkey and Switzerland
If this study is part of a multi-site performance study outside the EU/EEA/UK, please provide a list
of all participating non EU/EEA countries.
of all participating non-Loyela countries.
1.7 Performance study plan (PSP)
1.7 Performance study plan (PSP)
1.7 Performance study plan (PSP) PSP code:
PSP code:
PSP code:
PSP code:
PSP code: PSP version:
PSP code: PSP version:
PSP code: PSP version: PSP date:
PSP code: PSP version: PSP date: 1.8 Performance study title
PSP code: PSP version: PSP date:
PSP code: PSP version: PSP date: 1.8 Performance study title
PSP code: PSP version: PSP date: 1.8 Performance study title
PSP code: PSP version: PSP date: 1.8 Performance study title
PSP code: PSP version: PSP date: 1.8 Performance study title Full title:
PSP code: PSP version: PSP date: 1.8 Performance study title Full title:
PSP code: PSP version: PSP date: 1.8 Performance study title Full title: Short title:
PSP code: PSP version: PSP date: 1.8 Performance study title Full title:
PSP code: PSP version: PSP date: 1.8 Performance study title Full title: Short title:

Section 2: Performance study description

2.1 Per	erformance study characteristics	
	Surgically invasive sample-taking is done only for the purpose of the performance stu	ıdy
		باماد
	In the following case, does the specimen collection represent a major clinical to the subject? Yes No	risk
	to the subject: Tes No	
	Please provide a justification of your answer:	
	Interventional clinical performance study as defined in point (46) of article 2 from IVI	OR
	Conduct of the study involves additional invasive procedures or other risks for the su of the study	bjects
	Study involving companion diagnostics	
	In the following case, will only left-over samples be used in the study?	
	Yes No	
	PMPF study involving additional procedures that are burdensome or invasive, compa	ıred
	to those performed under the normal conditions of use	
	Other(s) characteristic(s):	
2 2 Day	evelopment stage in the framework of European regulation	
<u>2.2 De</u>	evelopment stage in the framework of European regulation.	

Post-market stage

Pre-market stage

2.3 Objectives and endpoint
Primary objective(s):
Cocondany objective/s)
Secondary objective(s):
Other objective(s):
Drimary and naint/c)
Primary endpoint(s):

Secondary endpoint(s):	
Other and a Cath	
Other endpoint(s):	
2.4 Synopsis of the performance study	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	
2.4 Synopsis of the performance study Overall synopsis:	

2.5 Planned number of subjects/sa	<u>mples</u>	
Geographic area	Subjects	Samples
In Europe:		
In Asia:		
In Africa:		
In North America:		
In South America:		
In Oceania:		
Total planned number of subjects/samples:		
2.6 Duration of performance study		
Estimated start date:		
Estimated end date:		
2.7 Population 2.7.1 Medical condition		
Is there an associated medical cond	ition?	
Yes No		
Is the medical condition considered	to be rare?	
Yes No		
2.7.2 Gender of subjects		
Female	Male	Other
2.7.3 Inclusion criteria		

2.7.4 Exclusion criteria		
2.7.5 Type of subjects that will be Healthy	e recruited for the per Patients	formance study Vulnerable population
·		, ,
Minors	Pregnant women	Breastfeeding women
Patients in emergency situations	Incapacitated	
Situations	subjects	
Other (please specify):		
2.7.6 Age range of the participan	ts to be included in th	e performance study
In utero		
Newborns (from 0 to 27 days)		
Infants and toddlers (from 28 day	s to 23 months)	
Children (from 2 to 5 years)		
Children (from 6 to 11 years)		
Adolescents (from 12 to 17 years)		
Adults (from 18 to 84 years)		

Elderly (from 85 years)

2.8 Scope of the device for performance study

2.8.1 Combined study Medical Device/In Vitro Diagnostic Medical Device?		
Yes	No	
If yes, please	provide the related identifi	cation number of the clinical study
2.8.2	Is the application submitte	ed in parallel with an application for a clinical trial on
medio	cinal products?	
Yes	No	
If yes, please	provide the EU Clinical Tria	l Number:
2.9 Coordinat	ting investigator	
First name:		
Last name:		
Address	Street name:	Street number:
	Postal code:	City:
	Country:	1
Telephone nu	mber:	
Email:		

Section 3: Device for performance study

3.1 Performance study

3.1.1 Device purposes

Physiological process or state

Pathological process or state

Congenital physical impairments

Congenital mental impairments

Predisposition to a medical condition or a disease

To determine the safety with potential recipients

To determine compatibility with potential recipients

To predict treatment response or reactions

To define therapeutic measures

Monitoring therapeutic measures

Specimen receptacle

3.1.2 Device type

Intended for self-testing	Calibrator
Intended for near-patient testing	Control material
Companion diagnostics	
Reagent	
Professional use	
Instrument	
Kit	
Sterile	
Software	

3.1.3 Device identifiers

Generic denomination			
Device trade name:		Model:	
Device name:			
European Medical Dev	ce Nomenclature (weblink):		
Medical device classific	ration:		·
(MDCG 2020-16)			

Classification rule:
Device description:
Intended purpose:
intended purpose.
If the device for performance study is a companion diagnostic, please provide the medicinal
substance(s) name(s) for which the device for performance study is referring to:
Does the device include tissues, cells and substances of human, animal or microbial origin?
Yes No
If yes, please provide further information on the tissues, cells, substances of human, animal or microbial origin:

CE marked device will be used?
Yes No
If yes, please provide the information in the box below.
To what extent is the intended purpose of the device in the performance study covered by the CE-
mark?
CE marked device will be used outside the scope of its CE mark
CE marked device will be used within the seems of its CE mark and no additional
CE marked device will be used within the scope of its CE mark and no additional
procedures are foreseen in the performance study
CE marked device will be used within the scope of its CE mark, but additional
procedures are foreseen in the performance study
Are those additional procedures considered to be burdensome and/or invasive?
Yes No
Please, comment why do you consider as such?
Information related to the Notified body involved, if applicable:
Notified body number:
Notified body name:
3.2 Previous performance study
Has the device for performance study been investigated within the EU previously?
Yes No
If yes, please provide the relevant reference number(s) (such as SIN, CIV-ID, other reference(s))
of the previous performance study.
of the previous performance study.
3.3 Scientific opinion/view
Has the device for performance study been subject to a national scientific opinion or Expert Panel
view? Yes No
If yes, please provide the relevant reference to this opinion:
·

3.4 Manufacturer of the device for performance study

Is the manu	facturer the same as	the sponsor?	
	Yes	No	
If no, please	fill in the requested	l information in section	n 3.4.1 and 3.4.2
3.4.	1 Manufacturer info	ormation	
Organisation	n name:		
Address	Street name:		Street number:
	Postal code:		City:
	Country:		
Telephone r	 number:		
Email:			
	Contact porson	of the manufacturer	
First name:	<u>contact person (</u>	or the manufacturer	
This manner			
Last name:			
		_	
Telephone r	number:		
Email:			
Lillail.			

3.4.2 Authorized representative

Organisation	name:	
Address	Street name:	Street number:
	Postal code:	City:
	Country:	
Telephone n	umhor:	
	umber.	
Email:		
	Contact person of the authorized represent	cativ <u>e</u>
First name:		
Last name:		
Telephone n	umber:	
Email:		

Additional devices for performance study could be added by using a duplicated section 3, in appendix to this application form.

4.1 Applicability of sec	ction 4			
Is there a comparator i		e performance study?		
	Yes	No		
If yes, the section form	4.2 needs to	be completed.		
4.2 Type of comparato	<u>or</u>			
In Vitro Diagnostic Medical Device				
Other, pleas	e specify:			
, , , , , , , , , , , , , , , , , , ,				
	_			
4.2.1 In Vitro D	Diagnostic Me	dical Device as comparator		
Is the comparator in vi	tro medical de	evice CE marked?		
·	Yes	No		
If yes, will the CE marked comparator in vitro medical device be used in the performance study				
within the scope of its CE mark?				
	Yes	No		
	163	110		
Canania dan aminatian				
Generic denomination	:			
Davisa trada ramas	1		Madali	
Device trade name:			Model:	
Davies name:				
Device name:	i aa Namaanala	* /		
European Medical Dev	ice Nomencia	ture (weblink):		
Medical device classific				
ivicultal device classific	Jacion.			

Section 4: Comparator

Classification rule:				
Device description:				
Intended purpose:				
intended purpose.				
Does the comparator origin?	device include	tissues, cells, and su	bstances of animal, hu	man or microbial
	Yes	No		
If yes, please provide microbial origin:	further informa	ation on the tissues,	cells, substances of hu	man, animal or

Additional comparator for performance could be added by using a duplicated section 3, in appendix to this application form.

Section 5: National information

5.1 Study site information

Please provide the list of sites taking part in the study performance

Name of institution	Site address	Investigator attached to this site	Contact information of investigators
		l .	

Additional sites could be added by using a duplicated section 5.1, in appendix to this application form

5.2 Ethics committee information

Select the applicable option:				
Ethics committee opinion available, in the following option,				
please select the Ethics committee opinion : Positive Negative				
Ethics committee opinion under review				
Ethics committee opinion is not mandatory before submission to the competent authority				
If an ethics committee has to be selected by the sponsor before submission, please provide the ethics committee information's below. Organisation name:				
	Street name:	Street	number:	
Address	Postal code:	City:		
	Country:			
	-			
Email:				
Ethics commitee state	ement: stand that the Competent Authority may o	contact the	Ethics Committee that is	
assessing or has assessed the application				

	nsidered as comr	mercial according to national legislation?
Yes	No	
5.4 Expected n	umber of subjects	recruited within the Member State
How many subjec applying to?	ts are expected to	be recruited into the study in the Member State you are
	•	"appendix of documents to attach" to identify clearly which this application/notification.
		n and documentation submitted with this application/notification is correct
		sted has been supplied. The device for performance study complies with the performance requirements, apart from those covered by the study
		as been taken to protect the health and safety of the patient and/or user.
		information collected for this application, has been done in compliance with
confirm that all the	study performance	

Date: (mm/dd/yy)

Position:

Name: